Table 1.
Baseline characteristics
| Total | By Body Mass Index (kg/m2) | |||
|---|---|---|---|---|
| (n=249) | <30 | ≥30 | p-value | |
| (n=139, 56%) | (n=110, 44%) | |||
| Median age, years | 59 | 58 | 59 | 0.02 |
| Hispanic | 0.11 | |||
| Yes | 16 (7%) | 12 (9%) | 4 (4%) | |
| No | 225 (93%) | 122 (91%) | 103 (96%) | |
| Unknown | 8 | 5 | 3 | |
| Race | 0.31 | |||
| White | 217 (89%) | 120 (88%) | 97 (90%) | |
| Black | 20 (8%) | 10 (7%) | 10 (9%) | |
| Asian | 4 (2%) | 4 (3%) | -- | |
| Other | 3 (1%) | 2 (1%) | 1 (1%) | |
| Unknown | 5 | 3 | 2 | |
| Self-reported comorbid conditions | ||||
| Diabetes | 32 (13%) | 11 (8%) | 21 (19%) | 0.009 |
| Hypertension | 101 (41%) | 43 (31%) | 58 (53%) | 0.0005 |
| High cholesterol | 77 (31%) | 38 (27%) | 39 (35%) | 0.17 |
| Heart disease | 13 (5%) | 8 (6%) | 5 (5%) | 0.67 |
| Osteoarthritis | 57 (23%) | 22 (16%) | 35 (32%) | 0.003 |
| Number of cardiovascular risk factors | 0.001 | |||
| 0 | 92 (37%) | 65 (47%) | 27 (25%) | |
| 1 | 74 (30%) | 37 (27%) | 37 (34%) | 0.0003* |
| ≥2 | 83 (33%) | 37 (27%) | 46 (42%) | 0.01** |
| Statin use | 59 (24%) | 30 (22%) | 29 (26%) | 0.38 |
| Aromatase Inhibitor (AI) | 0.45 | |||
| Anastrozole | 146 (59%) | 86 (62%) | 60 (55%) | |
| Exemestane | 29 (12%) | 16 (12%) | 13 (12%) | |
| Letrozole | 74 (30%) | 37 (27%) | 37 (34%) | |
| Median time since starting AI, years | 1.17 | 1.00 | 1.33 | 0.61 |
| Median time since last menstrual period, years | 9.4 | 8.4 | 10.1 | 0.89 |
*
Comparing 1or more vs. 0 risk factors.
**
Comparing 2 or more vs. 0 or 1 risk factors